SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs quarterly results beat expectations and lifted its outlook, with rapid U.S. commercial AI growth overtaking government revenue for the first time. The shares nevertheless fell, as traders debated whether strong growth was already priced in given the companys high valuation, while others viewed the selloff as a disconnect from the results.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples earnings beat estimates, but traders focused on expected margin pressure from rising memory costs and weaker-than-expected China, iPad, and wearables results, driving a selloff despite strong iPhone sales. The community is split between viewing the drop as an overreaction to a solid quarter and seeing the outlook and valuation as reasons for caution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs Sanofi partnership is the main focus after a milestone was triggered by the start of a Phase 3 COVID-flu combination trial. Bulls view it as validation of the licensing model and a source of future royalties, while skeptics point to modest vaccine sales and question whether the Q3 results will show meaningful recurring revenue.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

Semiconductor shares are under pressure as investors question whether heavy AI and data-center spending will generate adequate returns, alongside broader tech selling. Traders are split between fears of a deeper correction and dip-buyers looking for a rebound after the sharp losses.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstarts sharp selloff and repeated lows have traders focused on concerns about high interest rates, funding and debt, and the outlook for consumer lending ahead of earnings. Some expect further downside if results or guidance disappoint, while bullish traders argue the decline may be overdone and point to growth potential or a possible short squeeze.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

A report that nonprofit Usona may have submitted an FDA application for psilocybin in major depressive disorder has sparked fears that a competitor could reach the market before COMPASS Pathways COMP360 for treatment-resistant depression, pressuring its pricing and commercial opportunity. Traders debate whether Usonas MDD focus materially threatens COMPASSs TRD program, and some view the selloff as an overreaction; uncertainty over the report and COMPASSs own NDA timeline remains central.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is drawing attention ahead of the FDAs Nov. 22 decision on deramiocel for Duchenne muscular dystrophy, with traders focusing on the applications upper-limb function data and new commercial-hiring listings as possible signs of launch preparationnot confirmation of approval. Optimism about a limited upper-limb approval and potential short covering competes with concerns about the FDAs earlier advisory-panel vote and the risk of a rejection; some traders also cite INOs recent approval as a positive read-through, while leak claims remain speculation.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion centers on the U.S. midterm elections and how a possible shift in congressional control could affect DJT shares, with bearish traders anticipating pressure and bulls arguing the stock could rally. Many also characterize its moves as speculative pump-and-dump trading, while Iran-war and peace-talk headlines appear as a secondary source of market uncertainty.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells agreed all-stock acquisition of Lumentum is driving attention, with traders focused on shareholder dilution, the long path to closing, and whether the deals price and execution risks outweigh its AI-optics rationale. The sharp selloff has fueled criticism that Marvell overpaid, while some investors argue the combination could strengthen its position in AI data-center connectivity over the long term.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

Biotechs pullback and relative resilience are the main focus: traders say IBB is holding up better than small-cap XBI, while debating whether recent sector strength and upcoming large-biotech earnings can sustain momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Oculis Holding AG (OCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ --Pomerantz LLP is...

EyePoint (EYPT) Expected to Beat Earnings Estimates: Should You Buy?

EyePoint (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsPR NewswireNEW YORK, Oct. 20, 2026 EyePoint...

Why AZN, VSXY, EYPT Stocks Are Moving Premarket Today

Equity

A healthcare AI collaboration and a bullish retail outlook lift sentiment, while a Phase 3 trial setback puts EyePoint under pressure.

Why Did EYPT, CRWV, EOSE Stocks Tumble To 52-Week Lows Today? 

Investors grew wary of the companies’ ability to execute their business plans and manage their finances.


Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today

Major U.S. indices ended mixed on Monday, with the Dow Jones Industrial Average slipping 0.07% to 51,966.03.read more...

EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT) EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)PR...

Here's Why You Should Add EYPT Stock to Your Portfolio Now

EyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.

OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.  


EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>AstraZeneca shares rise premarket after it agreed to explore AI-driven tools with Oracle to help identify clinical trial candidates and speed up research.</li><li>Barclays raised its VSXY price target and maintained an ‘Overweight’ rating ahead of the retailer’s Q3 report.</li><li>EyePoint Pharmaceuticals shares fell after JPMorgan downgraded the stock to ‘Underweight.’</li></ul><p>Shares of AstraZeneca (AZN), Victoria’s Secret (VSXY) and EyePoint Pharmaceuticals (EYPT) moved in different directions in premarket trading on Tuesday. The moves followed a healthcare AI collaboration, an analyst price-target hike, and a downgrade after a clinical-trial setback.</p><p>AZN shares moved higher after Oracle Corp. (ORCL) announced an agreement to explore AI applications in clinical research. Similarly, VSXY gained after Barclays raised its price target, while EYPT fell after JPMorgan downgraded it.</p><h2 class="st-heading-2">AZN, ORCL Explore AI In Clinical Trials</h2><p><a href="https://stocktwits.com/symbol/AZN">AstraZeneca (AZN) shares</a> gained over 1.8% in premarket trading after Oracle announced a non-binding agreement with the company to explore how artificial intelligence and real-world data could help identify eligible clinical trial participants, speed up research and bring findings into everyday patient care.</p><p>The proposed collaboration would combine AstraZeneca’s scientific and therapeutic expertise with Oracle’s healthcare data, cloud infrastructure, AI, analytics and clinical workflow capabilities. The companies plan to explore tools that could help care teams identify suitable patients earlier, improve clinical trial efficiency and address patient recruitment challenges.</p><h2 class="st-heading-2">Barclays Raises VSXY Price Target</h2><p><a href="https://stocktwits.com/symbol/VSXY">Victoria’s Secret (VSXY) shares</a> gained nearly 1% in premarket trading after Barclays raised its price target to $112 from $106 while maintaining an ‘Overweight’ rating.</p><p>The firm remains constructive on the stock ahead of the company’s third-quarter report. According to the research note, transaction and traffic data point to continued momentum across the business.</p><h2 class="st-heading-2">EYPT Slides After JPMorgan Downgrade</h2><p><a href="https://stocktwits.com/symbol/EYPT">EyePoint Pharmaceuticals (EYPT) shares</a> fell nearly 4.4% after JPMorgan downgraded the stock to ‘Underweight’ from ‘Neutral.’ The firm did not provide a price target.</p><p>The downgrade followed EyePoint’s first Phase 3 trial of Duravyu for wet age-related macular degeneration, which failed to meet its primary endpoint. JPMorgan expects the shares to remain under pressure in the medium term.</p><h2 class="st-heading-2">AZN, VSXY, EYPT Stocks: Stocktwits Retail Sentiment</h2><p>Retail sentiment toward AstraZeneca was ‘neutral,’ unchanged in the past 24 hours, while message volume rose to ‘high’ from ‘normal’ during the same period.&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN shares</a> have fallen around 11% year-to-date.</p><p>Retail sentiment for Victoria’s Secret was ‘bullish,’ while message volume was ‘high,’ both unchanged over the past 24 hours.&nbsp;<a href="https://stocktwits.com/symbol/VSXY">VSXY stock</a> has gained over 193% since the beginning of this year.</p><p>For EyePoint Pharmaceuticals, the sentiment improved to ‘bullish’ from ‘bearish’ in the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ during the same period.&nbsp;<a href="https://stocktwits.com/symbol/EYPT">EYPT stock</a> has declined over 96% year-to-date.&nbsp;</p><p><strong>Also See:</strong>&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-nasdaq-futures-falling-premarket-crwv-nbis-tsla-spcx-mu-asts-nflx-sls-stocks-in-focus/cZxq8CeRBu1">Why Are Nasdaq Futures Falling Premarket? CRWV, NBIS, TSLA, SPCX, MU, ASTS, NFLX, SLS Stocks In Focus</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca PLC

EyePoint Pharmaceuticals Inc

Victoria`s Secret & Co

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$0.3748
Prev Close	$0.3484
Open	$0.35
Dividend Yield	0.00%
50-Day Moving Average	$3.11
Beta	1.15
Avg. Volume	16.59M
PE Ratio	-0.10

52-Week High	$19.11
52-Week Low	$0.3446
Market Capitalization	$30.04M
EPS (Annual)	-$3.17
Price to Book	0.19
Revenue Per Employee	$146,593.46

Feed

News

Sentiment

Earnings

Fundamentals

Info

EYPT Fundamentals